For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
16
views
37
references
 Top references
cited by
45
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      112
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency

      review-article
      Author(s): , MD, PhD
      Publication date (Electronic):
      Journal: Immunology and Allergy Clinics of North America
      Publisher: Elsevier Inc.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          During the last 2 decades, the continued development and the large-scale production of polyclonal immune serum globulin (ISG) preparations with improved safety and tolerability profiles have allowed treatment to focus on quality of life and long-term freedom from the complications of primary immune deficiency disease, rather than just on freedom from severe acute infections and survival. Available ISG preparations allow routine therapy by a variety of routes and regimens that can be tailored to suit individual patients. Continued vigilance is required, however, because problems with emerging diseases, and the costs and availability of ISG are likely to present continuing challenges.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: not found
          • Article: not found

          Agammaglobulinemia.

          C Bruton (1952)
          Article 0 comments Cited 101 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.

            Charlotte Cunningham-Rundles, P Busse, S S M Razvi (2002)
            Common variable immunodeficiency (CVID) is a primary immune disorder characterized by antibody deficiency and a decrease in serum IgG and IgA, IgM, or both levels at least 2 SDs below the mean for age and not attributed to other known immunologic disorders. These patients often present with frequent and severe episodes of pneumonia before diagnosis. The standard treatment, intravenous immunoglobulin (IVIG), has been available for the past 20 years. No large-scale study has compared the incidence of pneumonia in these patients before and after IVIG treatment. The aim of this study was to document the effectiveness of intravenous immunoglobulin treatment on the incidence of pneumonia in patients with CVID. We performed chart reviews and interviews of patients with laboratory-confirmed CVID seen at our clinical center. The number of episodes of pneumonia was documented before and after treatment with immunoglobulin replacement therapy. The histories of 50 patients were reviewed (mean current age, 42 +/- 16.3 years; age range, 10-78 years; 20 male and 30 female patients). Forty-two (84%) of the 50 patients with CVID had pneumonia at least once before receiving immunoglobulin treatment, and 11 of 42 of these patients had multiple episodes. After treatment with gamma globulin over a mean period of 6.6 +/- 5.2 years (range, <1-20 years), the number of patients experiencing pneumonia significantly decreased to 11 (22%) of 50. In most cases these patients had pneumonia in the first year of immunoglobulin treatment. The treatment of CVID with IVIG significantly reduces the incidence of pneumonia.
            Article 0 comments Cited 75 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.

              H Ochs, S Mankarious, K-H. Pyun … (1988)
              With the increased use of immunoglobulin for intravenous use (IGIV) as replacement therapy for patients with primary immunodeficiencies, a natural concern is whether such preparations demonstrate a normal turnover rate with regard to total IgG, individual IgG subclasses, and specific antibody titers. We have conducted such a pharmacokinetic study on a cohort of eight patients with an IGIV preparation, Gammagard. For total IgG, the half-life found was 25.8 days; for IgG1 it was 29.7 days; for IgG2 it was 26.9 days; and for IgG3 it was 15.7 days. The results are similar to those reported for endogeneous IgG. Half-lives for antibodies to S. minnesota (Re 595 mutant), cytomegalovirus, and S. pneumoniae were of the same order of magnitude as that for total IgG. We conclude that this IGIV preparation is catabolized in patients with primary immunodeficiency at a rate similar to that of native IgG in normal individuals.
              Article 0 comments Cited 73 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Melvin Berger
                Journal
                Journal ID (nlm-ta): Immunol Allergy Clin North Am
                Journal ID (iso-abbrev): Immunol Allergy Clin North Am
                Title: Immunology and Allergy Clinics of North America
                Publisher: Elsevier Inc.
                ISSN (Print): 0889-8561
                ISSN (Electronic): 1557-8607
                Publication date PMC-release: 20 April 2008
                Publication date (Print): May 2008
                Publication date (Electronic): 20 April 2008
                Volume: 28
                Issue: 2
                Pages: 413-437
                Affiliations
                Division of Pediatric Allergy and Immunology, Case Western Reserve University, University Hospitals of Cleveland/Rainbow Babies and Children's Hospital, 11100 Euclid Avenue, MS: RBC 6008B, Cleveland, OH 44106, USA
                Article
                Publisher ID: S0889-8561(08)00009-X
                DOI: 10.1016/j.iac.2008.01.008
                PMC ID: 7127239
                PubMed ID: 18424340
                SO-VID: 69197ca1-639f-4e70-9a4a-b8a5df3133e9
                Copyright © Copyright © 2008 Elsevier Inc. All rights reserved.
                License:

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Subject: Article

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content112

                See all similar

                Cited by45

                See all cited by

                Most referenced authors426

                See all reference authors